PANEL OF SERUM BIOMARKERS MAY PREDICT BENEFIT FROM BEVACIZUMAB (BEV) IN ADVANCED NSCLC PATIENTS

被引：0
|
作者：
Braun, Eduardo [1 ]
Fidler, Mary Jo [1 ]
Basu, Sanjib [1 ]
Gargaram, Anjali [2 ]
Walters, Kelly [2 ]
Fhied, Cristina [2 ]
Borgia, Jeffrey A. [2 ]
Bonomi, Philip D. [1 ]
机构：
[1] Rush Univ, Med Ctr, Div Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Div Biochem, Chicago, IL 60612 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S124 / S125
页数：2
相关论文
共 50 条
  • [21] Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
    Jantus-Lewintre, Eloisa
    Massuti Sureda, Bartomeu
    Gonzalez Larriba, Jose Luis
    Rodriguez-Abreu, Delvys
    Juan, Oscar
    Blasco, Ana
    Domine, Manuel
    Provencio Pulla, Mariano
    Garde, Javier
    Alvarez, Rosa
    Maestu, Inmaculada
    Perez de Carrion, Ramon
    Artal, Angel
    Rolfo, Christian
    de Castro, Javier
    Guillot, Monica
    Oramas, Juana
    de las Penas, Ramon
    Ferrera, Lioba
    Martinez, Natividad
    Serra, Olbia
    Rosell, Rafael
    Camps, Carlos
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
    Minari, Roberta
    Bonatti, Francesco
    Mazzaschi, Giulia
    Dodi, Alessandra
    Facchinetti, Francesco
    Gelsomino, Francesco
    Cinquegrani, Gloria
    Squadrilli, Anna
    Bordi, Paola
    Buti, Sebastiano
    Bersanelli, Melissa
    Leonetti, Alessandro
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Quaini, Federico
    Ardizzoni, Andrea
    Tiseo, Marcello
    TUMORI JOURNAL, 2022, 108 (01): : 47 - 55
  • [23] Serum Albumin Level Predicts the Survival Benefit of Chemotherapy in Elderly Advanced NSCLC Patients with Poor Performance Status
    Ikeda, S.
    Yoshioka, H.
    Ikeo, S.
    Morita, M.
    Sone, N.
    Niwa, T.
    Nishiyama, A.
    Yokoyama, T.
    Sekine, A.
    Ogura, T.
    Ishida, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2068 - S2068
  • [24] Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
    Reck, M.
    Barlesi, F.
    Crino, L.
    Henschke, C. I.
    Isla, D.
    Stiebeler, S.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1111 - 1120
  • [25] Prognostic Image Biomarkers in the Treatment of Patients with Locally Advanced NSCLC
    Tvilum, M.
    Lutz, C. M.
    Hoffmann, L.
    Khalil, A.
    Appelt, A.
    Alber, M.
    Grau, C.
    Schmidt, H. H.
    Kandi, M.
    Haraldsen, A.
    Mortensen, L. S.
    Holt, M. I.
    Knap, M.
    Moller, D. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E393 - E393
  • [26] A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC)
    Knox, Jennifer J.
    Qin, Rui
    Strosberg, Jonathan R.
    Kaubisch, Andreas
    El-Khoueiry, Anthony B.
    Bekaii-Saab, Tanios B.
    Erlichman, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] A serum metabolic fingerprint may predict advanced fibrosis due to NAFLD in a cohort of diabetic patients
    Forlano, Roberta
    Mullish, Benjamin H.
    Blanco, Jesus Miguens
    Danckert, Nathan
    Thursz, Mark
    Manousou, Pinelopi
    JOURNAL OF HEPATOLOGY, 2021, 75 : S540 - S540
  • [28] Carboplatin-paclitaxel bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with advanced NSCLC
    Van Groningen, H.
    Timmer-Bonte, A.
    Van den Hurk, D.
    Dohmen, M.
    Graaf, C. Smits-Van der
    Van der Drift, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [29] Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors
    Jia, Jingquan
    Li, Haiyan
    Dellinger, Andrew
    Pang, Herbert
    Russell, Karen Bullock
    Hurwitz, Herbert
    Nixon, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
    Wang, Yanni
    Zou, Jianling
    Li, Yun
    Jiao, Xi
    Wang, Yujiao
    Zhuo, Na
    Gao, Mengting
    Gong, Jifang
    Li, Jian
    Zhang, Xiaotian
    Wang, Xicheng
    Peng, Zhi
    Qi, Changsong
    Wang, Zhenghang
    Li, Jie
    Li, Yan
    Shen, Lin
    Zhang, Henghui
    Lu, Zhihao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345